Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
- 26 June 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 16 (7), 1111-1120
- https://doi.org/10.1517/13543784.16.7.1111
Abstract
Epigenetic regulation of gene transcription by small-molecule inhibitors of histone deacetylases (HDACs) is a novel cancer therapy. Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL). Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in Phase I development. In two Phase II trials, vorinostat 400 mg/day was safe and effective with an overall response rate of 24 – 30% in refractory advanced patients with CTCL including large cell transformation and Sézary syndrome. The common side effects of vorinostat, which are similar in all studies, include gastrointestinal symptoms, fatigue and thrombocytopenia and the most common serious event was thrombosis.Keywords
This publication has 48 references indexed in Scilit:
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic ActionJournal of Investigative Dermatology, 2005
- Signal transducer and activator of transcription (STAT) signalling and T‐cell lymphomasImmunology, 2005
- Cutaneous T-Cell Lymphoma: A Paradigm for Biological TherapiesLeukemia & Lymphoma, 2004
- Histone deacetylase inhibitors – a new tool to treat cancerCancer Treatment Reviews, 2004
- T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceBlood, 2004
- Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidJournal of Cellular Biochemistry, 2004
- Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic AnalysisJournal of Molecular Biology, 2004
- HLA-DR5 and DQB1*03 Class II Alleles Are Associated With Cutaneous T-Cell LymphomaJournal of Investigative Dermatology, 1996